Abstract
The WHO has called for pharmaceutical companies to stop selling the malaria drug artemisinin as a monotherapy because of concerns that this practice will precipitate resistance. According to the new WHO malaria treatment guidelines cases of uncomplicated falciparum malaria the most common type of the disease must be treated with artemisinin combination therapies (ACTs) and not with artemisinin by itself or any other single therapy. “So far there have been no reported treatment failures due to artemisinin drug resistance” says Pascal Ringwald a medical officer in WHO’s Roll Back Malaria initiative. “But organisms have been identified with a reduced sensitivity and that is not a good sign.” (excerpt)
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
